Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 1.20 (29.63%)
Spread: 0.50 (10.00%)
Open: 4.05
High: 5.40
Low: 3.90
Yest. Close: 4.05
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

N4 Pharma PLC - Posting of Annual Report and Notice of AGM

Fri, 27th Apr 2018 11:00

RNS Number : 3964M
N4 Pharma PLC
27 April 2018
 

N4 Pharma Plc

("N4 Pharma" or the "Company")

Posting of Annual Report and Notice of AGM

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which improves the delivery of existing drugs and novel vaccines and therapeutics, announces that its Annual Report and Accounts for the year ended 31 December 2017 together with the Notice of Annual General Meeting are today being posted to shareholders and are available from the Company's website at www.n4pharma.com.

 

The Company's Annual General Meeting will be held on 23 May 2018 at 10.00am at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR.

 

 

Enquiries:

 

N4 Pharma Plc

Nigel Theobald, CEO

 

Via Alma PR

Stockdale Securities

Tom Griffiths

Tel: +44(0)20 7601 6100

Alma PR

Josh Royston

Robyn Fisher

 

Tel: +44(0)778 090 1979

Tel: +44(0)754 070 6191

 

 

About N4 Pharma

 

N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma's reformulation work falls under two divisions:

• generic, already commercialised, drugs; and

• delivery of novel and existing vaccines and therapeutics.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra™, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

N4 Pharma's business model for vaccines is to undertake the required clinical work to demonstrate the capability of its delivery system as a cancer vaccine or therapeutic treatment so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKDLBLVZFEBBF
Date   Source Headline
30th Mar 20202:05 pmRNSSecond Price Monitoring Extn
30th Mar 20202:00 pmRNSPrice Monitoring Extension
25th Mar 20201:18 pmRNSChanges to AGM
25th Mar 20207:00 amRNSCovid-19 Project Update and operational update
16th Mar 202010:26 amRNSHolding(s) in Company

Login to your account

Don't have an account? Click here to register.